Evidence map›Paper›PMID 41845388›Full record

ArticleJournal of nanobiotechnology2026

Engineering BiTE-inspired IPSC-exosomes to potentiate CAR-T cell therapy against lung cancer.

Ronghao Wang, Guining Fu, Haozhao Dou, Mingyuan Hu, Zhanglin Li, Junwen Gan, Jiasheng He, Xiaojian Li, Guihong Zhang, Xianjun Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ronghao Wang *Department of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China.
Guining Fu *Department of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China.
Haozhao Dou *Department of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China.
Mingyuan Hu *Department of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China.
Zhanglin Li *Department of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China.
Junwen GanDepartment of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China.
Jiasheng HeDepartment of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China.
Xiaojian LiDepartment of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China.
Guihong ZhangDepartment of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China.
Xianjun LiDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, China. lixj277@alumni.sysu.edu.cn.
Tianchuan ZhuCenter for Infection and Immunity, Guangdong Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China. zhutch5@mail.sysu.edu.cn.
Qingdong CaoDepartment of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China. caoqd@mail.sysu.edu.cn.

Funding

the Excellent Young Talent Research Start-up Fund from the Fifth Affiliated Hospital of Sun Yat-sen University KY2024040006the National Natural Science Foundation of China 82303799the National Natural Science Foundation of China 82403895the Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0529300the Science and Technology Development Fund of the Macao SAR 0004/2021/AKPthe Talent-Attracting Fund from the Fifth Affiliated Hospital of Sun Yat-sen University 220904094208the Zhuhai Social Development Science and Technology Plan Project 2420004000280
6 · The paper itself

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy faces critical barriers in solid tumors, including poor infiltration, T cell exhaustion, and immunosuppressive microenvironments, resulting in response rates below 10%. Herein, we engineered an inhalable nanoplatform using induced pluripotent stem cell-derived exosomes (IEXOs) displaying bispecific PD-1/mesothelin (MSLN) single-chain variable fragments (scFv) and loaded with indole-3-propionic acid (IPA) for metabolic reprogramming. IEXOs demonstrated high yield and intrinsic antitumor properties, inhibiting Lewis lung carcinoma (LLC) cell proliferation and migration. The bispecific exosomes loaded with IPA (BIEXO@IPA) achieved efficient pulmonary delivery via nebulization with 79.3% tumor cell-specific uptake versus 47.9% for liposomes in orthotopic lung cancer models. BIEXO@IPA treatment reduced tumor burden by 87.9% and achieved 80% survival at 80 days. Mechanistically, BIEXO@IPA bridged PD-1

Indexed as

ExosomesImmunotherapy, AdoptiveInduced Pluripotent Stem CellsLung NeoplasmsReceptors, Chimeric AntigenAnimalsCarcinoma, Lewis LungCell Line, TumorCell ProliferationHumansIndolesMesothelinMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorSingle-Chain AntibodiesIndolesMesothelinProgrammed Cell Death 1 ReceptorReceptors, Chimeric AntigenSingle-Chain AntibodiesBispecific T cell engagersChimeric antigen receptor T cellsExosomesImmunotherapyIndole-3-propionic acidInduced pluripotent stem cellsLung cancer

Identifiers

PMID41845388
PMCPMC13107855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.